Overview

NCI Definition: A non-invasive adenocarcinoma of the breast characterized by a proliferation of monomorphic cells completely filling the lumina. The overall lobular architecture is preserved. It is frequently multifocal (90% in some series) and bilateral. It seldom becomes invasive; however there is an increased risk of infiltrating ductal adenocarcinoma. [1]

Breast lobular carcinoma in situs most frequently harbor alterations in PIK3CA, TP53, CDH1, KDM6A, and EP300 [2].

Most Commonly Altered Genes in Breast Lobular Carcinoma In Situ

PIK3CA Mutation, CDH1 Mutation, TP53 c.217-c.1178 Missense, TP53 Mutation, and TP53 Missense are the most common alterations in breast lobular carcinoma in situ [2].

Top Alterations in Breast Lobular Carcinoma In Situ

Significant Genes in Breast Lobular Carcinoma In Situ

BRCA1 +

BRCA2 +

ERBB2 +

PTEN +

TP53 +

Disease Details

Synonyms
Non-Infiltrating Lobular Carcinoma of the Breast, Lobular Breast Carcinoma In Situ, Non-Invasive Lobular Breast Carcinoma, Lobular carcinoma in situ, Lobular Carcinoma In Situ of the Breast, Non-invasive lobular breast carcinoma, LCIS, Non-Infiltrating Lobular Breast Carcinoma, Non-Infiltrating Lobular Carcinoma, Lobular Carcinoma In Situ (LCIS), Non-Infiltrating Lobular Carcinoma of Breast, Non-Invasive Lobular Carcinoma of Breast, Non-Invasive Lobular Carcinoma of the Breast, Lobular Carcinoma in situ, Lobular Carcinoma in situ of Breast, Non-infltrating lobular breast carcinoma, Lobular Ca in situ of Breast, Lobular Ca in situ of the Breast, Lobular Carcinoma In Situ of the Breast (LCIS, lobular carcinoma in situ
Parent(s)
Lobular Breast Carcinoma
OncoTree Name
Breast Lobular Carcinoma In Situ
OncoTree Code
LCIS

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.